School of Medicine
Showing 361-380 of 514 Results
-
Theodore Roth
Assistant Professor of Pathology
Current Research and Scholarly InterestsThe Roth Lab develops, applies, and translates scalable genetic manipulation technologies in primary human cells and complex in vivo tissue environments. Working with students, trainees, and staff with backgrounds across bioengineering, genetics, immunology, oncology, and pathology, the lab has developed CRISPR-All, a unified genetic perturbation language able to arbitrarily and combinatorially examine genetic perturbations across perturbation type and scale in primary human cells. Ongoing applications of CRISPR-All in the lab have revealed surprising capacities to synthetically engineer human cells beyond evolved cellular states. These new capacities to perturb human cell’s genetics beyond their evolved functionality drives ongoing work to understand the biology and therapeutic potential of synthetic cell state engineering - in essence learning how to build new human genes tailor made for a specific cell and specific environment to drive previously inaccessible therapeutic cellular functions.
-
Atif Saleem
Clinical Assistant Professor (Affiliated), Pathology Clinical
Staff, Pathology Operations supported expensesBioDr. Atif Saleem completed his residency training in Anatomic and Clinical Pathology, followed by fellowships in Hematopathology and Dermatopathology at Stanford. He is board certified in both Anatomic Pathology and Clinical Pathology, Hematopathology, and Dermatopathology. His interests include virus-associated neoplasms, medical education, and global health.
-
Darren Salmi
Clinical Associate Professor, Pathology
Current Research and Scholarly InterestsCardiovascular pathology, congenital heart disease, autopsy, medical education
-
Matteo Santoro Pharm.D., Ph.D.
Postdoctoral Scholar, Pathology
BioDr. Santoro joined Shamloo’s lab in March 2021 focusing his research on Parkinson’s disease, neuronal vulnerability, and identification of therapeutic markers in relation to α-synucleinopathies. Prior to his arrival at Stanford, he held a position as a clinical monitor at Syneos Health where he gained key knowledge needed to translate lab-based findings into clinical and commercial applications. Previously, Dr. Santoro held a postdoctoral position at the University of Aberdeen (Scotland, UK) working on amyloid-beta extracts from Alzheimer’s disease patients. During his postdoctoral research, Dr. Santoro designed and optimized a cost-effective and rapid assay for the measurement of toxic amyloid-beta species in human biofluids. In 2017, he obtained his Ph.D. (4-year program) at the University of Aberdeen on Parkinson’s disease (PD), immunology, and behavior. The major findings Ph.D. findings were the following: 1) the characterization of a small protein called HMGB1 as an inflammatory mediator in PD; 2) the motor and non-motor behavioral characterization of three neurotoxin based mouse models of PD, 3) the characterization of the innate immune response in PD through the toll-like receptor signaling pathways 4) evaluation of the effects of chronic systemic inflammation on both resident and infiltrating immune cells in the CNS. In 2012 Dr. Santoro attained his Pharm.D. in chemistry and pharmaceutical technology (5-year program) at the University of Calabria (Italy) during which he undertook an internship at the King’s College London (SGDP Centre) and worked for over a year on a rat model of stroke.
-
Ansuman Satpathy
Associate Professor of Pathology
Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.
